Aktuellt
SENASTE
Redeye provides an update following SenzaGen’s Q1 report. Sales during the quarter aligned with our expectations; however, we highlight the quarterly EBITDA and argue that SenzaGen is one step closer to profitability. We only make some minor estimate changes and our fair value range remains intact.
LÄS MER
